Neon joins the biotech IPO fi­es­ta on Nas­daq, bag­ging $100M in the lat­est dis­play of en­thu­si­asm for drug de­vel­op­ers

Neon Ther­a­peu­tics just bare­ly made it in­to the big H1 group of biotech IPOs that’s land­ed so far this year.

Hopes of help­ing open a new chap­ter in can­cer ther­a­py with their brand of high­ly per­son­al­ized neoanti­gen vac­cines — along with plen­ty of in­sid­er sup­port — got them out of the gate on Nas­daq at $16 a share — land­ing in the mid­dle of the range with a $100 mil­lion raise.

The biotech will start trad­ing to­day as $NT­GN.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER